2. Search Result
Search Result
Pathways Recommended: Metabolic Enzyme/Protease
Results for "

Metabolic diseases

" in MedChemExpress (MCE) Product Catalog:

8200

Inhibitors & Agonists

16

Screening Libraries

40

Fluorescent Dye

107

Biochemical Assay Reagents

609

Peptides

45

Inhibitory Antibodies

2188

Natural
Products

889

Isotope-Labeled Compounds

30

Click Chemistry

120

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147296
    Omesdafexor

    MET642

    		 FXR Metabolic Disease Inflammation/Immunology Cancer
    Omesdafexor is a FXR agonist. Omesdafexor can be used in the research of liver disease or a metabolic inflammation-mediated disease .
    Omesdafexor
  • HY-44154
    PSB-CB5

    		Others Metabolic Disease
    PSB-CB5 is a potent and selective antagonist of GRP18. PSB-CB5 has the potential for the research of metabolic disease and obesity .
    PSB-CB5
  • HY-155830
    PDE4-IN-14

    		Phosphodiesterase (PDE) Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    PDE4-IN-14 (Compound 1) is a PDE4 inhibitor that can be used in the study of PDE4-related diseases (such as inflammatory and immune diseases, cancer, and metabolic diseases, etc.) .
    PDE4-IN-14
  • HY-122210
    T521

    		E1/E2/E3 Enzyme Metabolic Disease Cancer
    T521 is an inhibitor of E3 ligase. T521 can be used in cancer and metabolic disease related research .
    T521
  • HY-149605
    KHK-IN-4

    		Ketohexokinase Metabolic Disease
    KHK-IN-4 (compound 14) is a potent ketohexokinase (KHK) inhibitor. KHK-IN-4 can be used for fructose metabolic disease research .
    KHK-IN-4
  • HY-146742
    PPARγ agonist 2

    		PPAR Metabolic Disease
    PPARγ agonist 2 is a potent PPARγ partial agonist and can be used for metabolic disease research .
    PPARγ agonist 2
  • HY-162016
    IP6K-IN-1

    		Others Metabolic Disease
    IP6K-IN-1 (compound 24) is a potent and selective inhibitor of IP6K with an IC50 of 0.896 μM. IP6K-IN-1 can used in study metabolic disease .
    IP6K-IN-1
  • HY-160169
    Necrosis inhibitor 2

    		Others Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Necrosis inhibitor 2 (Compound B19) is a cell necrosis inhibitor. Necrosis inhibitor 2 can be used to study diseases related to the necrosis pathway, including inflammation, tumors, metabolic diseases and neurodegenerative diseases .
    Necrosis inhibitor 2
  • HY-160169A
    Necrosis inhibitor 2 (hydrocholide)

    		Others Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Necrosis inhibitor 2 hydrocholide (Compound B19) is a cell necrosis inhibitor. Necrosis inhibitor 2 hydrocholide can be used to study diseases related to the necrosis pathway, including inflammation, tumors, metabolic diseases and neurodegenerative diseases .
    Necrosis inhibitor 2 (hydrocholide)
  • HY-151963
    PPARγ/GR modulator 1

    		PPAR Glucocorticoid Receptor Metabolic Disease
    PPARγ/GR modulator 1 is an orally active dual agonist of PPARγ and glucocorticoid receptor (GR), with Kis of 3.3 and 33.6 μM, respectively. PPARγ/GR modulator 1 can be used for the research of metabolic diseases, such as diabetes .
    PPARγ/GR modulator 1
  • HY-P4040
    Ac-D-DGla-LI-Cha-C

    		HCV Protease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases .
    Ac-D-DGla-LI-Cha-C
  • HY-147108
    Mitochondria degrader-1

    		Mitochondrial Metabolism Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Mitochondria degrader-1 (example 5) is a potent mitochondria degrader. Mitochondria degrader-1 induces the degradation of the injured mitochondria by the autophagy mechanism. Mitochondria degrader-1 can be used for the research of neurodegenerative disease, cancer, inflammatory disease, age-related disease, metabolic disease, mitochondrial disease or Down's disease .
    Mitochondria degrader-1
  • HY-142917
    THR-β agonist 4

    		Others Metabolic Disease
    THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72) .
    THR-β agonist 4
  • HY-143613
    THR-β agonist 2

    		Others Metabolic Disease
    THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .
    THR-β agonist 2
  • HY-143614
    THR-β agonist 3

    		Others Metabolic Disease
    THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6) .
    THR-β agonist 3
  • HY-W008151
    Diphenyl Phosphate

    		Mitochondrial Metabolism Metabolic Disease
    Diphenyl Phosphate inhibits growth and energy metabolism in zebrafish and mice in a sex-specific manner. Diphenyl Phosphate can inhibit the activity of SDH (respiratory complex II), reduce the expression of CPT1 and disrupts the integrity of the mitochondrial membrane. Diphenyl Phosphate may be used in research on metabolic diseases .
    Diphenyl Phosphate
  • HY-117918
    ST-1892

    		FXR Metabolic Disease Inflammation/Immunology
    ST-1892 (compound 14) is a highly potent FXR agonist (EC50=7.2 nM) that can be used to study diseases or disorders caused by metabolic inflammation .
    ST-1892
  • HY-158130
    FKBP51-Hsp90-IN-1

    		FKBP HSP Neurological Disease Metabolic Disease Cancer
    FKBP51-Hsp90-IN-1 (Compound D10) is a selective inhibitor of the FKBP51-Hsp90 protein-protein interaction, with an IC50 value of 0.1 μM against FKBP51. FKBP51-Hsp90-IN-1 can be used in the research of stress-related diseases, Alzheimer's disease, and metabolic disorders .
    FKBP51-Hsp90-IN-1
  • HY-153476
    GIP/GLP-1 dual receptor agonist-1

    		GCGR Metabolic Disease
    GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .
    GIP/GLP-1 dual receptor agonist-1
  • HY-E70410
    NAD Synthetase

    NAD+ Synthetase; Nicotinamide adenine dinucleotide synthetase

    		 Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    NAD synthetase is responsible for the final step in the synthesis of nicotinamide adenine dinucleotide (NAD). The Km values for NAD, ATP, and ammonia of NAD synthetase from Escherichia coli are 200 μM, 11 μM, and 0.65 μM, respectively, while the Km values for NAD, ATP, and ammonia of NAD synthetase from yeast are 170 μM, 190 μM, and 64 μM, respectively. NAD synthetase can be used for enzymatic assays to determine ATP, ammonia, urea, or creatinine, and is also suitable for enzymatic cycling methods. Additionally, NAD synthetase holds potential for research into metabolic diseases, cancer, aging, and neurodegenerative diseases .
    NAD Synthetase
  • HY-134325
    8-OH-cAMP

    8-Hydroxy-cAMP

    		 PKA Cardiovascular Disease Metabolic Disease
    8-OH-cAMP (8-Hydroxy-cAMP) is a polar, membrane-impermeable cyclic adenosine monophosphate analog that is resistant to mammalian cyclic nucleotide-dependent phosphodiesterases. As a polar PKA agonist, 8-OH-cAMP is used to study the role of cAMP in the development and progression of cardiovascular and metabolic diseases .
    8-OH-cAMP
  • HY-D1168
    Oil Red O
    3 Publications Verification

    		 Fluorescent Dye Metabolic Disease
    Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses .
    Oil Red O
  • HY-136561
    GRK5-IN-2

    		G Protein-coupled Receptor Kinase (GRK) Metabolic Disease
    GRK5-IN-2 (compound 707), a pyridine-based bicyclic compound, is a potent G-protein-coupled receptor kinase 5 (GRK5) inhibitor. GRK5-IN-2 regulates the expression and/or release of insulin and is useful for the metabolic disease research .
    GRK5-IN-2
  • HY-163472
    PR280

    		Others Metabolic Disease Cancer
    PR280 is a potent inhibitor of dihydroceramide desaturase 1 (Des1) (IC50=700 nM). PR280 forms hydrogen bonds with the amino acid residues of Des1, and its cyclopropenone group may form a coordination with the iron center, thus stabilizing the binding to the active site of Des1 and inhibiting the sphingosine lipid synthesis pathway of dihydroceramide (dhCer) to form ceramide. PR280 can be used in the study of diseases related to sphingosine lipid metabolism, such as cancer and metabolic diseases .
    PR280
  • HY-B1779
    Sucrose
    5 Publications Verification

    D-(+)-Saccharose

    		 Endogenous Metabolite Metabolic Disease Cancer
    Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preference, and diabetes, et al .
    Sucrose
  • HY-160577
    DOG-IM4

    		Liposome Others
    DOG-IM4 can be used to synthesize nanoparticles to deliver antigen-encoding nucleic acids. It could be used to try to target autoimmune diseases, rare blood or metabolic diseases, allergies, cancer or infectious diseases .
    DOG-IM4
  • HY-117516
    SR10067

    		REV-ERB Neurological Disease Metabolic Disease
    SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC50 values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders .
    SR10067
  • HY-P10302
    GLP-1R/GIPR agonist-1

    		GLP Receptor Insulin Receptor Metabolic Disease
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R/GIPR agonist-1
  • HY-W768338
    Sucrose-13C

    D-(+)-Saccharose-13C

    		 Isotope-Labeled Compounds Metabolic Disease Cancer
    Sucrose- 13C is 13C labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose?can be applied in some animal models, including metabolic disease, obesity,?diet on preference,?and diabetes, et al .
    Sucrose-13C
  • HY-50861
    AZD3988

    		Acyltransferase Metabolic Disease
    AZD3988 is an orally active diacylglycerol acyl transferase-1 (DGAT-1) inhibitor. AZD3988 has excellent DGAT-1 (human) potency with an IC50 value of 0. 6 nM. AZD3988 can be used for the research of metabolic diseases such as diabetes, obesity .
    AZD3988
  • HY-159120
    ZG-2291

    		HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    ZG-2291 is a selective inhibitor targeting FIH (Factor Inhibiting HIF) with oral activity. By binding to FIH, ZG-2291 promotes a conformational flip of a catalytically important tyrosine, enabling selective inhibition of FIH without affecting other 2OG oxygenases in the JmjC subfamily. ZG-2291k enhances thermogenesis in ob/ob mice and improves obesity-related symptoms and metabolic dysfunctions. ZG-2291 holds promise for research in the field of obesity-related diseases .
    ZG-2291
  • HY-151616
    sEH inhibitor-10

    		Epoxide Hydrolase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    sEH inhibitor-10 (Compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC50=0.5 μM). sEH inhibitor-10 maintains high cycloeicosatrienoic acid (EETs) levels by inhibiting sEH, thereby reducing inflammation, regulating endothelial tone, improving mitochondrial function, and reducing oxidative stress. sEH inhibitor-10 has good research potential in metabolic, renal and cardiovascular diseases .
    sEH inhibitor-10
  • HY-146731
    PPARγ agonist 1

    		PPAR Cardiovascular Disease Metabolic Disease
    PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .
    PPARγ agonist 1
  • HY-B1779R
    Sucrose (Standard)

    		Endogenous Metabolite Metabolic Disease Cancer
    Sucrose (Standard) is the analytical standard of Sucrose. This product is intended for research and analytical applications. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose?can be applied in some animal models, including metabolic disease, obesity,?diet on preference,?and diabetes, et al .
    Sucrose (Standard)
  • HY-W768340
    Sucrose-13C6-1

    D-(+)-Saccharose-13C6-1

    		 Isotope-Labeled Compounds Metabolic Disease Cancer
    Sucrose- 13C6-1 is 13C labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose?can be applied in some animal models, including metabolic disease, obesity,?diet on preference,?and diabetes, et al .
    Sucrose-13C6-1
  • HY-163358
    SLC3037

    		NOD-like Receptor (NLR) NEKs Cardiovascular Disease Neurological Disease Inflammation/Immunology
    SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases .
    SLC3037
  • HY-146398
    AMPK activator 6

    		AMPK Metabolic Disease
    AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
    AMPK activator 6
  • HY-125990
    SLC13A5-IN-1

    		Sodium Channel Cardiovascular Disease Metabolic Disease
    SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of  14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5 .
    SLC13A5-IN-1
  • HY-160168
    BTK-IN-31

    		Btk Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders .
    BTK-IN-31
  • HY-162122
    PPARα/γ agonist 3

    		PPAR Inflammation/Immunology
    PPARα/γ agonist 3 (Compound 4) is a dual agonist of PPARα/γ. PPARα/γ agonist 3 has anti-inflammatory activity, significantly reducing inflammatory markers such as IL-6 and MCP-1 on THP-1 macrophages through NF-κB activation. PPARα/γ agonist 3 can be used in the study of metabolic syndrome and metabolic dysfunction-related fatty liver disease (MAFLD) .
    PPARα/γ agonist 3
  • HY-134493
    Butyrate-Vitamin D3

    Butyrate-Cholecalciferol; Butyrate-Colecalciferol

    		 VD/VDR Metabolic Disease Inflammation/Immunology Cancer
    Butyrate-Vitamin D3 (Butyrate-Cholecalciferol) is a derivative of vitamin D3 in which a hydroxyl group in the vitamin D3 molecule is replaced by a butyric acid group. Butyrate-Vitamin D3 affects gene expression and cell function and has certain anti-inflammatory effects. Butyrate-Vitamin D3 can be used in the study of immune regulation, metabolic diseases and cancer .
    Butyrate-Vitamin D3
  • HY-149339
    hnNOS-IN-2

    		NO Synthase Neurological Disease
    hnNOS-IN-2 (compound 17) is a human neuronal nitric oxide synthase (hnNOS) inhibitor with good metabolic stability. hnNOS-IN-2 can be used for research in neurodegenerative diseases .
    hnNOS-IN-2
  • HY-137608
    Uridine 5'-O-thiodiphosphate

    UDP-β-S

    		 P2Y Receptor Cardiovascular Disease
    Uridine 5'-O-thiodiphosphate (UDP-β-S) is a stable analog of UDP. As a selective agonist of P2Y6 receptor, Uridine 5'-O-thiodiphosphate has higher metabolic stability and can be used in the study of cardiovascular diseases .
    Uridine 5'-O-thiodiphosphate
  • HY-U00358
    Compound 2

    		Others Metabolic Disease
    Compound 2 is an active compound used for the research of metabolic bone diseases.
    Compound 2
  • HY-148104
    ACSS2-IN-2

    		Others Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC50 value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer .
    ACSS2-IN-2
  • HY-107901
    Pparδ agonist 1

    		PPAR Cardiovascular Disease Metabolic Disease
    Pparδ agonist 1 is a PPAR-δ agonist, with an EC50 of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.
    Pparδ agonist 1
  • HY-108557
    TCS 2510

    CAY10598

    		 Prostaglandin Receptor Metabolic Disease
    TCS 2510 is a selective EP4 agonist. TCS 2510 can be used for the research of metabolic diseases .
    TCS 2510
  • HY-B0051
    Carbazeran

    		Phosphodiesterase (PDE) Metabolic Disease
    Carbazeran, a potent phosphodiesterase inhibitor, is aldehyde oxidase substrate. Carbazeran can be used for the research of metabolic disease .
    Carbazeran
  • HY-132830
    Sebetralstat

    KVD900

    		 Kallikrein Metabolic Disease
    Sebetralstat (KVD900) is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases .
    Sebetralstat
  • HY-153800A
    (R)-Monlunabant

    (R)-MRI-1891; (R)-INV-202

    		 Cannabinoid Receptor Metabolic Disease
    (R)-Monlunabant ((R)-MRI-1891) is a CB1 receptor mediators for research of obesity and metabolic disease
    (R)-Monlunabant

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: